Once limited to the clinical and research settings, direct-to-consumer (DTC) hereditary genetic tests are now available on the open market. Given the medical significance of these tests, there is a pressing need to address the unique ethical questions that arise when cancer susceptibility testing moves from the clinic to the DTC market. In this Viewpoint, we outline the current state of DTC genetic testing for hereditary cancer susceptibility, discuss ethical questions related to informed consent and the disclosure of consumers’ test results, outline research needs, and recommend steps that DTC companies can take to promote informed consent and demonstrate the safe return of results.
Kilbride MK, Domchek SM, Bradbury AR. Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests. JAMA Oncol. 2018;4(10):1327–1328. doi:10.1001/jamaoncol.2018.2439
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.